The 100 Days Mission and What Makes a Vaccine Platform Truly Ready

The short answer

Platform readiness is several distinct properties that have to align at the same time. A vaccine platform is ready for rapid pandemic response when it can be re-coded for a new pathogen without rebuilding its manufacturing and analytical processes, when supply chains and facilities can scale that process without reinvention, and when regulators already understand the technology from prior use. The Coalition for Epidemic Preparedness Innovations (CEPI) published two frameworks in 2025 that make these dimensions explicit, which means readiness claims can now be appraised against a structured checklist rather than accepted on the strength of marketing language alone.

Why the 100 Days Mission set the bar where it did

The 100 Days Mission asks the field to have a safe, effective, and accessible vaccine ready for initial authorization and manufacturing at scale within 100 days of recognizing a new pandemic pathogen. The number is deliberately provocative. During COVID-19, according to CEPI, the first safe and effective vaccines were being rolled out within 326 days of the viral genome becoming available, a genuinely fast timeline by historical standards and still far longer than 100 days. CEPI frames the stakes in modeled terms: had vaccines been available roughly 100 days after the January 2020 genome release, a substantial share of pandemic mortality might have been averted. Those counterfactual figures are model outputs, not measured results, and should be read as illustrating the direction and scale of potential benefit rather than a precise forecast.

The mission is now embraced by G7 and G20 leaders as a shared preparedness goal. That endorsement matters less for the political signal than for what it forced: a concrete, testable definition of what has to be true, in advance, for a 100-day response to be physically possible.

The dimensions of readiness, made explicit

CEPI's Platform Readiness Dashboard, published in the journal Vaccines in 2025, breaks platform maturity into six dimensions rather than a single score. Adaptability captures how readily a platform can be modified for a new pathogen without changing its manufacturing or analytical processes. Compatibility asks whether the platform fits the specific outbreak, including prior experience with the relevant viral family and suitability for the target population. Suitability covers practical deployment factors such as stability, safety, cost, and intellectual property clearance. The regulatory dimension reflects how familiar regulators already are with the platform and whether it has prior authorization history. Manufacturing covers scalability, technology transfer potential, and supply chain resilience. Facility readiness covers good manufacturing practice (GMP) compliance and analytical testing capacity.

The dashboard applies to nucleic acid-based (RNA and DNA), protein subunit, and viral vectored platforms, and explicitly excludes live attenuated and inactivated approaches from its scope. Each dimension is scored with a simple color code, from high to low readiness, with a separate category for missing information. That last category is the quietly honest part of the design. It records what is not yet known, which is exactly the information a rigorous reader wants and a promotional summary tends to omit.

The central lesson of the dashboard is structural. A platform can be excellent on one axis and weak on another, and an outbreak response depends on balanced performance across all of them at once. A technology that adapts to a new sequence in days but has no qualified regional manufacturing is not 100-day ready, and neither is one that has abundant capacity yet no regulatory track record.

Where the 100 days actually goes

The second CEPI framework, a Chemistry, Manufacturing and Controls (CMC) rapid response framework also published in Vaccines in 2025, is useful because it converts the abstract goal into a schedule and shows where the time is spent. It organizes the work into five functional areas: drug substance and product process, formulation and stability, analytical methods, material controls and supply chain, and manufacturing facilities. Each has to be substantially pre-built during the quiet interpandemic period, not improvised during an outbreak.

The framework is candid that 100 days is only achievable in the most favorable case. It lays out three scenarios. A familiar pathogen with a known vaccine candidate can plausibly reach conditional approval near day 100, with clinical trial material released at scale within weeks and process and analytical validation completed in parallel. A related but less-characterized pathogen pushes the timeline to roughly 150 to 180 days because it requires new safety data first. A genuinely unknown pathogen requiring fresh antigen design and preclinical work extends to roughly 200 to 230 days. Presenting these as distinct scenarios is itself a discipline against overclaiming, because it ties the headline number to a specific and often optimistic set of starting conditions.

The framework also identifies where responses realistically break. Without manufacturing partnerships positioned in advance, especially in the regions affected, the search for a manufacturer, the scheduling, the technology transfer, and the subsequent regulatory filing introduce delays that no amount of platform speed can recover. Regulatory readiness is treated the same way: rapid conditional approval depends on alignment with health authorities agreed before the outbreak, including a commitment to complete the usual safety and validation work afterward. Speed at the front end is borrowed against obligations at the back end, not substituted for them.

How to appraise a readiness claim

For a reader evaluating any statement that a platform is pandemic-ready, these frameworks suggest a short set of questions. Ready on which dimension, adaptability, manufacturing, or regulatory, and is the claim silent on the others? Ready for which scenario, a familiar pathogen or an unknown one? Is there qualified, ideally regional, manufacturing capacity, or only a laboratory process? Has a regulator engaged with this platform before, or would authorization start from zero? And what has been left in the missing-information category rather than scored green?

Readiness is a moving target that has to be maintained during calm periods, when there is no outbreak to justify the spending and no headline to reward it. The value of CEPI's published dimensions is that they let funders, developers, and the public tell durable preparation from a confident sentence, which is the distinction the next response will depend on. This article is educational and is not medical advice.